China Medical GatewayLoading your healthcare gateway…

CAR-T Cell Therapy in China

Overview

CAR-T cell therapy re-engineers a patient’s own T lymphocytes to recognize and attack their cancer. It has produced remarkable remissions in relapsed and refractory leukemias, lymphomas and myeloma after conventional therapy has failed.

Chinese centers were among the world’s first to run pivotal CAR-T trials and have treated thousands of patients; domestically developed CAR-T products are approved and available, in several cases years ahead of some international markets.

Symptoms & Signs

Symptoms are those of the underlying blood cancer: recurrent fevers and night sweats

Progressive fatigue and anemia despite treatment

Swollen lymph nodes or an enlarging abdomen from lymph-node or marrow disease

Frequent infections from impaired immunity

Bone pain from marrow infiltration

Disease that relapses after, or fails to respond to, two or more prior lines of therapy — the classic CAR-T indication

Diagnosis

Re-staging of the underlying malignancy: PET-CT for lymphoma, marrow studies for leukemia

Marrow biopsy confirming disease and cell-of-origin

Molecular testing — clonality, cytogenetics and targeted NGS panels

Assessment of heart, lung, kidney and liver function required before cell therapy

Screening for active infection, which must be controlled first

HLA and general transplant-compatibility review

Treatment Options

Leukapheresis collecting the patient’s T cells for engineering

Lymphodepleting chemotherapy preparing the body for CAR-T infusion

Single CAR-T infusion, followed by inpatient monitoring for cytokine-release syndrome and neurotoxicity

Management of side effects with tocilizumab-class and steroid protocols

Post-infusion surveillance: CAR-T persistence testing and disease monitoring

Salvage planning including allogeneic transplant for eligible patients after CAR-T

Advanced Technologies & Novel Drug

Domestically developed CD19 CAR-T products approved for lymphoma and leukemia

BCMA-directed CAR-T for multiple myeloma

GMP cell-processing laboratories with closed manufacturing systems

Cytokine-release-syndrome prediction and neurotoxicity monitoring protocols

Novel dual-target and armored CAR constructs in clinical programs at Chinese centers

Hospital & Specialist

Return to Home